Oramed Pharm (ORMP) AI Stock Analysis

• Market Cap: $136.52M
• Dividend Yield: N/A
• Average Volume (3M): 210.74K
• Price to Earnings (P/E): 3.4
• Beta (1Y): 0.65
• Revenue Growth: N/A
• EPS Growth: 814.20%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 39,802,456
• 10 Day Avg. Volume: 339,860
• 30 Day Avg. Volume: 210,739
• PEG Ratio: 0.01
• Price to Book (P/B): 0.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.72
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: $3.50 ▲(20.27% Upside)

The score is held back mainly by weak operating fundamentals and persistent cash burn despite a strong, low-debt balance sheet. Offsetting that, technicals are in an uptrend, valuation looks inexpensive on P/E, and corporate events (liquidity gains and a cash dividend) are supportive.

Positive Factors

Low leverage / strong balance sheet

Very low leverage materially reduces solvency and refinancing risk, giving Oramed durable financial flexibility to fund multi‑year clinical programs, pursue licensing or partnership deals, and withstand development setbacks without immediate distress financing.

Scilex monetization and ongoing optionality

Realized cash from Scilex plus remaining notes, warrants and a long‑dated royalty provide durable non‑operating cash sources and upside optionality. These instruments extend runway, reduce near‑term financing pressure and can fund R&D or strategic partnerships.

Rights plan strengthens governance protections

A shareholder rights plan (poison pill) protects the board from hostile takeovers, preserving management control to execute multi‑year clinical and commercialization strategies. This structural governance tool supports continuity of long‑term R&D plans.

Negative Factors

Persistent negative operating and free cash flow

Sustained negative operating and free cash flow indicates structural cash burn from R&D and operations, necessitating recurring external funding or asset monetization. This undermines self‑funding for trials and risks dilution or curtailed programs if monetization stalls.

Minimal revenue and inconsistent earnings quality

Tiny recurring revenue and persistent operating losses show the business model has not yet generated commercial sales. Positive net income driven by non‑recurring items signals low earnings quality and limited sustainable margin generation from core operations.

JV termination increases execution risk

Terminating the JV removes partner capital, capabilities and shared execution responsibilities, shifting full development, regulatory and commercialization burden to Oramed. This raises funding needs and operational risk for the oral insulin program over the coming months.

Oramed Pharm Business Overview & Revenue Model

Company Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

How the Company Makes Money

Oramed Pharmaceuticals generates revenue primarily through the development and potential commercialization of its oral drug delivery technology. The company's revenue model is heavily reliant on successful clinical trials and the subsequent approval and licensing of its products. Oramed partners with pharmaceutical companies to co-develop and license its technologies, receiving milestone payments and royalties from these collaborations. Additionally, the company may engage in research and development service agreements, contributing to its revenue streams. However, as a clinical-stage company, its current earnings are mostly derived from partnerships and investments aimed at advancing its clinical programs.

Oramed Pharm Financial Statement Overview

Summary

Oramed Pharm's financial performance is mixed. The income statement is weak due to zero revenue and negative EBIT, while the balance sheet is strong with a high equity ratio. Cash flow is negative, indicating liquidity issues.

Income Statement

Oramed Pharm's income statement reflects significant challenges, primarily due to zero revenue in the TTM, a negative EBIT, and fluctuating net income figures. The lack of revenue growth and negative margins highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio, indicative of financial stability. However, the debt-to-equity ratio is low, providing some leverage risk, but overall liabilities remain manageable relative to equity.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating potential liquidity issues. The operating cash flow to net income ratio is unfavorable, suggesting challenges in converting income into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.00M	0.00	1.34M	2.70M	2.70M	2.71M
Gross Profit	-79.00K	-193.00K	1.34M	2.70M	2.70M	2.62M
EBITDA	58.42M	-14.87M	7.32M	-36.98M	-25.04M	-11.31M
Net Income	43.85M	-19.10M	5.53M	-37.76M	-22.24M	-11.51M
Balance Sheet
Total Assets	220.49M	155.28M	220.55M	161.64M	128.00M	44.63M
Cash, Cash Equivalents and Short-Term Investments	134.69M	141.93M	162.05M	155.72M	94.14M	39.90M
Total Debt	860.00K	372.00K	51.62M	894.00K	533.00K	75.00K
Total Liabilities	18.16M	9.93M	57.66M	10.49M	11.48M	11.75M
Stockholders Equity	203.28M	146.26M	163.82M	151.81M	115.77M	32.88M
Cash Flow
Free Cash Flow	-11.03M	-8.43M	-10.55M	-29.20M	-21.56M	-12.52M
Operating Cash Flow	-11.01M	-8.41M	-10.29M	-28.70M	-21.18M	-12.44M
Investing Cash Flow	23.22M	105.82M	-73.04M	30.21M	-22.26M	4.63M
Financing Cash Flow	-2.15M	-52.04M	51.98M	11.56M	101.39M	23.79M

Oramed Pharm Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Positive. The current price of 2.91 is below the 20-day moving average (MA) of 3.06, above the 50-day MA of 2.75, and above the 200-day MA of 2.36, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 70.58 is Negative, neither overbought nor oversold. The STOCH value of 89.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORMP.

Oramed Pharm Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORMP	63 Neutral	$136.52M	3.42	24.38%	―	―	814.20%
WHWK	56 Neutral	$124.42M	18.92	-13.82%	―	-42.62%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALXO	48 Neutral	$73.19M	-0.71	-118.95%	―	―	31.98%
QNCX	47 Neutral	$149.78M	-2.42	-247.78%	―	―	2.26%
SPRB	45 Neutral	$85.62M	-0.92	-167.93%	―	-90.18%	-17.93%

Oramed Pharm Corporate Events

Oramed Pharm Announces Dividend After Scilex Payment Gain

On January 7, 2026, Oramed Pharmaceuticals reported receiving an $18 million payment from Scilex Holdings Inc., marking full satisfaction of obligations under their Option Agreement and lifting Oramed’s realized returns on its original $99.5 million Scilex investment to $118 million. The company continues to hold a $27 million note and a $12 million convertible note in Scilex, along with warrants and a nine-year royalty interest, leaving further potential upside from the relationship and underscoring Oramed’s strategy of leveraging investment gains alongside its clinical operations. Reflecting these gains and surplus capital, Oramed’s board approved a cash dividend of $0.25 per share, expected to distribute about $10.5 million to shareholders on January 26, 2026, to investors of record as of January 16, 2026, signaling confidence in the company’s financial position and providing a direct return to equity holders.

The most recent analyst rating on (ORMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.

Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation

On December 31, 2025, Oramed Pharmaceuticals Inc. announced that board member Leonard Sank notified the company of his intention to resign from its board of directors, effective January 1, 2026, after serving 18 years with the company. The company stated that Sank’s departure was not due to any disagreement related to operations, policies or practices, signaling an orderly governance transition rather than a sign of internal conflict, though the exit of such a long‑tenured director may still mark a notable change in the board’s composition and institutional knowledge for stakeholders.

The most recent analyst rating on (ORMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.

Oramed Pharm Completes Warrant Sale, Boosting Liquidity

On July 22, 2025, Oramed Pharmaceuticals Inc. entered into an option agreement with Scilex Holding Company granting Scilex the right to repurchase warrants held by Oramed to buy a total of 6,500,000 shares of Scilex common stock at a nominal exercise price, in two tranches, for an agreed aggregate purchase price of $27 million. Scilex repurchased the first tranche of warrants covering 3,130,000 shares on September 30, 2025 for $13 million following a $750,000 option fee, and on December 30, 2025 completed the second and final tranche for the remaining 3,370,000 warrants for $14 million, plus a further $750,000 option fee, resulting in Oramed receiving total cash proceeds of $28.5 million from the transaction, bolstering its liquidity and financial flexibility.

The most recent analyst rating on (ORMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.

Oramed Pharm Declares Dividend Amidst Takeover Defense

On November 16, 2025, Oramed Pharmaceuticals’ Board of Directors declared a dividend of one common stock purchase right for each outstanding share of common stock, payable on November 27, 2025. This Rights Agreement is designed to protect shareholders in the event of a hostile takeover by ensuring fair treatment and enhancing the Board’s negotiation capabilities. The Rights become exercisable if a person or group acquires 15% or more of the company’s stock, allowing holders to purchase shares at a favorable rate, while the Rights held by the acquiring party become void. The Rights will expire three years after adoption unless redeemed or exchanged earlier.

Oramed Pharm Repurchases Shares, Ends Joint Venture

On October 20, 2025, Oramed Pharmaceuticals repurchased and retired 1,155,367 shares from Hefei Tianhui Biotech Co., Ltd. for approximately $2.58 million. The joint venture with HTIT was terminated due to unmet financial conditions, but Oramed will continue its oral insulin program independently. The company has made significant investments in biomedical companies like Alpha Tau Medical, Scilex Holdings, and BioXcel Therapeutics, generating substantial returns and positioning itself for future growth. Oramed plans to reward shareholders with a one-time dividend and is actively pursuing new partnerships to expand its market potential.